Alerts will be sent to your verified email
Verify Email
BETA
|
Beta Drugs
|
Novartis
|
Syncom Formulations
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
21.73 % | 5.71 % | 8.81 % |
|
5yr average Equity Multiplier
|
1.75 | 2.57 | 1.5 |
|
5yr Average Asset Turnover Ratio
|
1.04 | 0.22 | 0.79 |
|
5yr Avg Net Profit Margin
|
11.97 % | 11.91 % | 7.78 % |
|
Price to Book
|
0.0 | 2.59 | 4.89 |
|
P/E
|
49.6 | 21.91 | 39.19 |
|
5yr Avg Cash Conversion Cycle
|
15.7 Days | -22.58 Days | 84.02 Days |
|
Inventory Days
|
43.83 Days | 44.4 Days | 27.61 Days |
|
Days Receivable
|
87.61 Days | 38.62 Days | 123.89 Days |
|
Days Payable
|
113.94 Days | 118.8 Days | 93.18 Days |
|
5yr Average Interest Coverage Ratio
|
13.71 | 32.45 | 39.83 |
|
5yr Avg ROCE
|
27.85 % | 4.99 % | 12.74 % |
|
5yr Avg Operating Profit Margin
|
21.58 % | 10.55 % | 9.47 % |
|
5 yr average Debt to Equity
|
0.23 | 0.0 | 0.2 |
|
5yr CAGR Net Profit
|
31.07 % | 53.24 % | 19.56 % |
|
5yr Average Return on Assets
|
12.53 % | 2.24 % | 5.89 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
66.73 % | 70.68 % | 50.57 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.02 % | 0.0 | 4.45 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Beta Drugs
|
Novartis
|
Syncom Formulations
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|